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Background
Fluorescence in situ hybridization (FISH) analysis can provide important information in 
the management of patients with hematologic malignancies. However, FISH performed 
in addition to G-banded karyotype can be labor-intensive and expensive. The aim of this 
study was to evaluate whether FISH gives additional information in the setting of adequate 
conventional cytogenetics in cases of hematologic malignancies.
Methods
Bone marrow aspirates were obtained from 135 patients at diagnosis (56 AML, 32 MDS, 
20 ALL, and 27 MM) between 2005 and 2010. Interphase FISH was performed using the 
following probes: BCR/ABL1, AML1/ETO, PML/RARA, CBFB, MLL, EGR1, CEP8, and 
D7S486 for AML; CEP8, D20S108, EGR1, and D7S486 for MDS; BCR/ABL1, MLL, CDKN2A
(p16),  ETV6, and 6q21/c-myc for ALL; IgH, TP53, D13S25, IgH/CCND1, IgH/MAF, 
IgH/FGFR3, and 1q21/8p21 for MM. We compared the results of FISH with the corre-
sponding aberrations identified by G-banded karyotype.
Results
Additional genetic aberrations detected by FISH (which were not identified by G-banded 
karyotype) were 4%, 9%, 50%, and 67% in AML, MDS, ALL, and MM, respectively. In ALL, 
CDKN2A and ETV6 FISH revealed additional genetic aberrations in 33% and 28% of cases, 
respectively. In MM, FISH was of benefit in detecting IgH, D13S25, TP53, and 1q21 re-
arrangements, not detected by G-banded karyotype (31%, 36%, 20%, and 40%, re-
spectively).
Conclusion
These results suggest that performing FISH in addition to G-banded karyotype may con-
tribute little additional genetic information in AML and MDS, whereas routine FISH analy-
sis appears to be an efficient screening method in ALL and MM.
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INTRODUCTION
  Karyotypic investigations, including fluorescence in situ 
hybridization (FISH), have become increasingly important 
in the detection of hematologic malignancies [1, 2]. In cases 
where cytogenetic analysis is hampered by low in vitro mi-
totic activity of cancer cells, poor chromosome morphology, 
considerable complexity, or a normal karyotype, FISH analy-
sis has provided a rapid and reliable detection of specific 
abnormalities in both mitotic and interphase cells [1, 2]. 
Both conventional G-banded karyotype and FISH analyses 
are currently integral components in the management of 
patients with hematologic malignancies.
  However, in view of limited laboratory and health care 
resources, FISH can be a labor-intensive, time-consuming, 
and expensive procedure, particularly if a specific abnormal-
ity has already been detected by G-banded karyotype. 
Therefore, the FISH approach should be strategically planned 
in order to contribute information additional to that provided Korean J Hematol 2010;45:171-6.
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Table 1. Patient characteristics.
Diagnosis AML
a) MDS
b) ALL
c) MM
N o .  o f  c a s e s 5 63 22 02 7
Age (years)
Median (range) 50 (0-80) 37 (15-87) 64 (3-72) 67 (46-87)
Sex (M：F) (n) 32：24 13：19 12：81 2 ：15
Karyotype (n)
  Normal
  Abnormal
  Culture failure
23
32
1
8
24
0
6
13
1
18
9
0
a)Included 18 AML with recurrent chromosomal abnormalities
[t(8;21) (n=6), t(15;17) (n=8), inv(16) (n=3), MLL (n=1)], 4 AML 
with myelodysplasia-related changes, and 34 AML, NOS, 
b)In-
cluded refractory cytopenia with unilineage dysplasia (n=16), 
refractory cytopenia with multilineage dyaplasia (n=13), refractory
anemia with excess of blasts (n=2), MDS-unclassifiable (n=1), 
c)Included B-lineage (n=15), T-lineage (n=4), mixed phenotype 
acute leukemia (n=1).
Abbreviations: AML, acute myeloid leukemia; MDS, myelody-
splastic syndrome; ALL, acute lymphoblastic leukemia; MM, 
multiple myeloma.
by conventional G-banded karyotype.
  The aim of this study was to evaluate the clinical utility 
of FISH in addition to G-banded karyotype and to propose 
a practical approach for FISH in the detection of hematologic 
malignancies, including acute myeloid leukemia (AML), 
myelodysplastic syndrome (MDS), acute lymphoblastic leu-
kemia (ALL), and multiple myeloma (MM).
MATERIALS AND METHODS
1. Patients
  The study group included 135 patients with hematologic 
malignancies (56 AML, 32 MDS, 20 ALL, and 27 MM) be-
tween 2005 and 2010. The characteristics of the patients 
are shown in Table 1.
2. Conventional cytogenetics
  Cytogenetic studies were performed with unstimulated 
24- and 48-hour cultures, using fresh bone marrow aspirates 
obtained from the 135 patients at diagnosis. When possible, 
at least 20 metaphases per sample were analyzed, and kar-
yotypes were described according to the International System 
for Human Cytogenetic Nomenclature (ISCN, 2009) [3].
3. FISH
  FISH studies of the 135 patients at diagnosis were per-
formed on fresh bone marrow aspirates or fixed cells obtained 
from bone marrow cultures for conventional cytogenetics. 
Commercially available probes (Abbott/Vysis, Downers Grove, 
IL, USA and Kreatech, Amsterdam, Netherlands) were used. 
The AML panel included BCR/ABL1 dual color, dual fusion 
translocation probe; AML1/ETO dual color, dual fusion trans-
location probe; PML/RARA dual color, dual fusion trans-
location probe; CBFB dual color, break-apart rearrangement 
probe; MLL (11q23) dual color, break-apart rearrangement 
probe; EGR1 (5q31)/D5S23, D5S721 dual color probe; CEP8 
SpectrumOrange probe; and D7S486 (7q31) SpectrumOrange/ 
CEP7 SpectrumGreen probe. The MDS panel included CEP8 
SpectrumOrange probe; D20S108 (20q12) SpectrumOrange 
probe; EGR1 (5q31)/D5S23, D5S721 dual color probe; and 
D7S486 (7q31) SpectrumOrange/CEP7 SpectrumGreen probe. 
The ALL panel included BCR/ABL1 dual color, dual fusion 
translocation probe; MLL dual color, break-apart rearrange-
ment probe; CDKN2A (9p21, p16) SpectrumOrange/CEP9 
SpectrumGreen probe; ETV6 (12p13) dual color, break-apart 
rearrangement probe; and 6q21/c-myc dual color probe. The 
MM panel included, IgH dual color, break-apart rearrange-
ment probe; TP53 SpectrumOrange probe; D13S25 (13q14.3) 
SpectrumOrange probe; IgH/CCND1 dual color, dual fusion 
translocation probe; IgH/MAF dual color, dual fusion trans-
location probe; IgH/FGFR3 dual color, dual fusion trans-
location probe; and 1q21/8p21 dual color probe. All probes 
except 6q21/c-myc and 1q21/8p21 (Kreatech) were provided 
by Abbott/Vysis. At least 200 interphase cells were scored 
for each probe by two independent experienced examiners.
RESULTS
1. AML (Table 2)
  FISH studies confirmed the corresponding abnormalities 
identified by G-banded karyotype in all of the AML samples. 
Additional abnormalities were d e t e c t e d  b y  F I S H  i n  o n l y  
two cases (4%). In 1 case with unsuccessful culture, AML1 
(RUNX1) gain was identified in 66% of interphase cells by 
FISH. In the other case, characterized by a complex karyotype 
with marker chromosomes and abnormalities of chromosome 
5, 17, 18, and 19, FISH detected MLL gain in 80% of inter-
phase cells.
2. MDS (Table 2)
  FISH confirmed the results of both normal and abnormal 
karyotype identified by G-banded karyotype. Abnormalities 
additional to those identified by G-banded karyotype were 
identified by FISH in 3 patients with normal karyotype (2 
patients, 20q deletion in 5-6% of interphase cells; 1 patient, 
7q deletion in 3% of interphase cells).
3. ALL (Tables 2 and 3)
  Clonal abnormalities were found in 65% and 80% of pa-
tients by G-banded karyotype and FISH, respectively. 
Additional abnormalities were identified by FISH in 50% 
of patients. Compared with G-banded karyotype, CDKN2A 
and ETV6 FISH revealed additional genetic aberrations in 
33% and 28% of cases, respectively. Two patients showed 
ETV6 gain using FISH, corresponding to the hyperdiploidy 
or hypertriploidy by G-banded karyotype. In 2 patients, 
ABL1 deletions unassociated with t(9;22) were identified 
by FISH.Korean J Hematol 2010;45:171-6.
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Table 2. Abnormalities detected by FISH in addition to G-banded 
karyotype.
N
Additional
detection rate (%)
Abnormal 
rate (%)
AML
Total 56 4 50
BCR/ABL1 48 0 2
AML1/ETO 48 2 23
PML/RARA 48 0 19
CBFB 45 0 7
MLL 48 2 4
EGR1 17 0 6
D7S486 22 0 5
CEP8 2 0 50
MDS
Total 32 9 34
CEP8 32 0 16
D20S108 32 6 13
EGR1 32 0 3
D7S486 32 3 6
ALL
Total 20 50 80
BCR/ABL1 20 10 35
MLL 19 5 5
CDKN2A 18 33 44
ETV6 18 28 33
6q21/c-myc 11 0 9
MM
Total 27 67 93
IgH 26 31 50
TP53 25 20 20
D13S25 25 36 52
IgH/CCND1 27 19 37
IgH/FGFR3 19 11 21
IgH/MAF 19 0 11
1q21 20 40 55
8p21 20 15 15
Abbreviation: FISH, fluorescence in situ hybridization. see Table 1.
Table 3. Additional genetic aberrations identified by FISH in ALL.
Case 
no.
G-banded karyotype FISH (% of rearranged cells)
1 46,XY[20] CDKN2A heterozygous deletion (66%)
2 46,XY[20] ETV6 break-apart (70%)
3 46,XX[1] CDKN2A homozygous (81%), heterozygous (4%) deletion
4 46,XX[20] CDKN2A homozygous (80%), heterozygous (3%) deletion
5 46,XY[20] CDKN2A homozygous deletion (11%)
6 46,XY[20] MLL deletion (87%), ETV6 break-apart (83%)
7 46,XY,add(9)(p22),add(16)(p13.3)[cp13]/46,XY[7] ABL1 deletion (76%), ETV6 break-apart (81%)
8 50,X,-X,+5,del(6)(q22),+7, der(8)t(8;9)(q24;p13), del(9)(p13),
der(9) t(1;9)(q11;p22),+13, t(14;18)(q32;q21),+der(18)t(14;18),
+mar[9]/50, idem, add(10)(q22)[11]
ETV6 gain (54%)
9 79,XXY,+4,+6,+8,+10,+10,+11,+21,+21,+21,+mar[2]/46,XY[18] CDKN2A gain (28%), ETV6 gain (15%) 
10 47,XY,+21c[19] ABL1 deletion (80%), CDKN2A deletion (76%) 
Abbreviations: FISH, fluorescence in situ hybridization; ALL, acute lymphoblastic leukemia.
4. MM (Tables 2 and 4)
  Clonal abnormalities were detected in 33% and 93% of 
patients by G-banded karyotype and FISH, respectively. 
Additional abnormalities were identified by FISH in 67% 
of patients, and among these, 89% had a normal karyotype 
as determined by G-banded karyotype. FISH was of benefit 
in detecting IgH, D13S25, TP53, and 1q21 rearrangements 
that were not detected by G-banded karyotype (31%, 36%, 
20%, and 40%, respectively).
DISCUSSION
  In this study, the percentages of additional genetic aberra-
tions identified by FISH (which were not detected by 
G-banded karyotype) were 4%, 9%, 50%, and 67% in AML, 
MDS, ALL, and MM, respectively.
  In AML and MDS, FISH did not add any relevant in-
formation to that already provided by G-banded karyotype 
with regard to specific chromosomal abnormalities. Similar 
to our result, a previous study showed that AML FISH profile 
tests revealed additional genetic abnormalities only in 8% 
of cases [4]. Another study showed that the discrepancy 
between G-banded karyotype and FISH for the diagnosis 
of AML is 7% [5]. Previous studies evaluating the utility 
of FISH in cases of MDS reported the detection of 6% or 
fewer abnormalities by FISH in addition to those detected 
by G-banded karyotype [6-13]. Other studies, however, have 
detected up to approximately 15% of additional abnormalities 
using FISH [14-16]. One study suggested that FISH testing 
may be informative only in MDS cases with culture failure 
or intermediate- to high-grade MDS cases with normal kar-
yotype, indicating that cases with low-grade MDS and normal 
karyotypes do not appear to benefit from FISH testing [13]. 
Taken together, in the setting of adequate cytogenetic study, 
the sensitivity of the two techniques in detecting clinically 
significant chromosomal abnormalities seems to be similar, 
and FISH may have limited utility in the cases of AML Korean J Hematol 2010;45:171-6.
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Table 4. Additional genetic aberrations identified by FISH in MM.
Case no. G-banded karyotype FISH (% of rearranged cells)
1 46,XX[20] D13S25 loss (54%)
2 45,X,-Y,?add(1)(q42),?del(11)(q23)[1]/46,XY[19] IgH break-apart (17%), TP53 deletion (6%), 1q21 gain (15%)
34 6 , X Y [ 2 0 ] IgH break-apart (16%), IgH/CCND1 rearrangement (13%)
4 46,XX,del(1)(p21)[2]/46,XX[18] D13S25 deletion (36%), 1q21 gain (19%), 8p21 deletion (19%)
5 46,XX[20] IgH break-apart (30%), IgH/CCND1 (57%), TP53 deletion (9%)
64 6 , X Y [ 2 0 ] IgH break-apart (11%), CCND1 (11q13) gain (4%), 1q21 gain (52%)
7 46,XX[20] IgH break-apart (27%), D13S25 deletion (21%), 1q21 gain (20%) 
84 6 , X Y [ 2 0 ] IgH break-apart (15%), TP53 deletion (14%), 1q21 gain (15%)
94 6 , X Y [ 2 0 ] IgH break-apart (15%), D13S319 deletion (20%), IgH/FGFR3 (16%)
10 46,XX[20] D13S319 deletion (21%), 1q21 gain (13%)
11 46,XY[20] TP53 gain (35%), CCND1 gain (24%), 1q21 gain (31%)
12 46,XX[20] D13S319 deletion (10%)
13 46,XY[20] IgH break-apart (6%)
14 46,XY[20] D13S319 deletion (23%)
15 46,XX[20] IgH break-apart (5%), D13S25 deletion (4%)
16 46,XX[20] TP53 deletion (9%)
17 46,XX[20] CCND1 gain (12%), 8p21 deletion (15%), TP53 deletion (39%)
18 46,XX[20] TP53 deletion (44%), D13S319 deletion (58%), 1q21 gain (67%), 
8p21 gain (62%)
Abbreviations: FISH, fluorescence in situ hybridization; MM, multiple myeloma.
or MDS. 
  In contrast, FISH, particularly in the cases of lymphoid 
malignancies, becomes an invaluable tool for identifying spe-
cific genetic changes other than G-banded karyotype. One 
study showed that ALL FISH profile tests revealed additional 
genetic aberrations not detected by G-banded karyotype in 
up to 49% of cases, and among these, ETV6/RUNX1 (TEL/ 
AML1) abnormalities were frequently detected (44%), fol-
lowed by the abnormal CDKN2A (25%) and hyperdiploidy 
(18%) [4]. A further study also demonstrated that G-banded 
karyotype failed to detect a considerable part of the 
ETV6/RUNX1 ( TEL/AML1) translocation (sensitivity 6%) 
[17]. As expected, FISH is of benefit in the detection of 
ETV6 and CDKN2A rearrangements, since these rearrange-
ments are cytogenetically cryptic and invisible. On the other 
hand, the sensitivity of G-banded karyotype for the detection 
of BCR/ABL1 and MLL rearrangements in ALL is relatively 
high (80% and 85%, respectively) [17]. Consistent with pre-
vious studies, our study showed that in ALL, ETV6 and 
CDKN2A genetic abnormalities, which were not identified 
by G-banded karyotype, could be additionally detected by 
FISH (28% and 33%, respectively).
  As reported previously, FISH is useful for improving the 
detection rate of genetic abnormalities in MM, whereas con-
ventional cytogenetics detects only 30-50% of abnormalities 
due to the low in vitro mitotic index of abnormal clones 
[18-25]. In this study, the detection rate of genomic aberra-
tions in MM increased from 67% to 93% using FISH, com-
pared with G-banded karyotype.
  FISH has been performed extensively to detect genomic 
aberrations in hematologic malignancies; however, in view 
of limited laboratory resources, it may be an expensive 
procedure. Here, we propose a strategy for cost-effective 
FISH utilization based on our results (Fig. 1). Importantly, 
this strategy should be based on the premise of cytogenetic 
adequacy (analyzing more than 20 consecutive, well-stained, 
well-spread metaphases). If a sufficient number of meta-
phases with morphology good enough to detect microscopic 
abnormalities cannot be analyzed, this strategy should not 
be applied. 
  With respect to ALL and MM, routine FISH analysis is 
needed, irrespective of karyotypic results (normal or abnor-
mal), since, as shown in this study, FISH can provide relevant 
information additional to that provided by G-banded kar-
yotype (Tables 2-4). In order to detect aneuploidy, it may 
be necessary to include centromere probes for chromosome 
5, 9, and 15 in the MM FISH panel [20, 22]. Here, we 
propose a FISH panel for adult B-lineage ALL; a FISH panel 
for children was not considered in this study. 
  In contrast to ALL and MM, an appropriate strategy should 
be selected in AML and MDS, depending on the results 
of G-banded karyotype. We recommend routine FISH analy-
sis in cases with a complex karyotype, because FISH can 
identify details of aberrations that cannot be resolved by 
G-banded karyotype alone. In addition, in cases with few 
or no mitotic cells, routine FISH analysis would be of benefit 
for obtaining clinically relevant information regarding 
aberrations. In AML or MDS with a normal karyotype, cer-
tain specific probes could be used to detect cryptic aberrations 
undetectable by G-banded karyotype. Among FISH probes 
that we did not evaluate in the present study, the TP53 
probe may be needed in cases with complex karyotypes 
or insufficient metaphases; this is because the TP53 deletion 
is known to be associated with a poor prognosis [26, 27].Korean J Hematol 2010;45:171-6.
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Fig. 1. Proposal for a cost-effective utilization of FISH in hematologic malignancies (*corresponded to specific chromosomal abnormalities identified
by G-banded karyotype).
  Of particular relevance, FISH analysis may be a superior 
method for disease monitoring, considering that G-banded 
karyotype could be hampered by a low in vitro mitotic activ-
ity of cancer cells after treatment. Therefore, if specific chro-
mosomal abnormalities are detected by G-banded karyotype 
at diagnosis, FISH analysis using target probes corresponding 
to the specific chromosomal abnormalities is needed to inves-
tigate specific abnormal FISH signal patterns for use of mon-
itoring markers during follow-up. An advantage of FISH 
over G-banded karyotype is that it requires considerably 
less time and effort. Therefore, apart from our proposal, 
FISH using specific target probes could be utilized in the 
initial assessment as an adjunct to G-banded karyotype, when 
critical genetic aberrations (such as PML/RARA rearrange-
ment) should be rapidly identified to determine the best 
therapeutic approaches.
  In addition to G-banded karyotype and FISH, PCR techni-
ques are currently being employed. Of particular interest, 
multiplex reverse-transcription PCR can be used to simulta-
neously identify numerous different translocations or chro-
mosomal rearrangements. To detect fusion transcripts or 
translocations, either PCR or FISH could be used. However, 
PCR techniques are unable to identify deletions or amplifica-
tions that can be readily identified by FISH, and therefore 
it is unlikely that these techniques will serve as a substitute 
for FISH. Further study is needed to develop efficient and 
cost-effective strategies that combine the use of G-banded 
karyotype, FISH, and PCR techniques.
  In conclusion, this study suggests that in the setting of 
an adequate karyotype of AML and MDS, routine FISH test-
ing contributes little, if any, further genetic information. 
In contrast, FISH panel testing for ALL and MM appears 
to be an efficient screening method, and routine FISH analysis 
should remain the method of choice. Finally, a consensus 
needs to be reached between laboratories as to the practical 
strategies for cost-effective utilization of FISH combined with 
G-banded karyotype. 
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